Emerging drugs for the management of cancer treatment induced bone loss

Expert Opinion on Emerging Drugs

Volumn 15, Issue 2, 2010, Pages 323-342

  Bertoldo, Francesco ^a   Pancheri, Serena ^a   Zenari, Sonia ^a   Boldini, Stefania ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Androgen deprivation therapy; Aromatase inhibitors; Bisphosphonates; Cancer treatment induced bone loss; Denosumab

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTIANDROGEN; AROMATASE INHIBITOR; ARZOXIFENE; BALICATIB; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CATHEPSIN K INHIBITOR; CLODRONIC ACID; DENOSUMAB; ESTROGEN RECEPTOR; FULVESTRANT; IBANDRONIC ACID; LASOFOXIFENE; LETROZOLE; LEUPRORELIN; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TAMOXIFEN; TOREMIFENE; UNINDEXED DRUG; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ARTHRALGIA; BACKACHE; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER PATIENT; CANCER TREATMENT INDUCED BONE LOSS; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; ESOPHAGUS ULCER; EVIDENCE BASED MEDICINE; FATIGUE; FLU LIKE SYNDROME; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; INFECTION; JAW OSTEONECROSIS; LEG PAIN; MEDLINE; MENOPAUSAL SYNDROME; MULTIPLE CYCLE TREATMENT; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; QUALITY OF LIFE; REFLUX ESOPHAGITIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION; VERTEBRA FRACTURE;

EID: 77952847410     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728211003631385     Document Type: Review

References (180)

1. Pfeilschifter J, Dieli IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000;18:1570-1593
2. Mincey BA. Osteoporosis in women with breast cancer. Curr Oncol Rep 2003;5:53-57
3. American Cancer Society. Breast Cancer Facts & Figures 2005 - 2006. Available from www.cancer.org
4. Smith MR. Therapy insight: osteoporosis during hormone therapy for prostate cancer. Nat Clin Pract Urol 2005;2:608-615
5. Smith MR, McGovern FJ, Fallon MA, et al. Low bone mineral density in hormone naïve men with prostate carcinoma. Cancer 2001;91:2238-2245
6. Hussain SA, Weston R, Stephenson RN, et al. Immadiate dual energy Xray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipultion. BJU Int 2003;92:690-694
7. Ryan CW, Huo D, Stallings JW, et al. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 2007;70:122-126
8. Li H, Stampfer MJ, Hollis JB, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLos Med 2007;4 (3):e103
9. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-164
10. Camacho P, Dayal A, Diaz J, et al. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteporosis. J Clin Oncol 2009;26;33:5380-5385
11. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001;86(8):3555-3561
12. Hirbe A, Morgan EA. Skeletal complication of breast cancer therapies. Clin Cancer Res 2006;12(Suppl 20):6309-6314
13. Kanis JA, McCloskey EV, Powles T, et al. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999;79:1179-1181
14. Chen Z, Maricic M, Bassford TL, et al. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 2005;165:552-558
15. Saarto T, Blomqvist C, Valimaki M, et al. Chemical castration induced by adjuvant cyclophosphoamide, methotrexate, and fluorouracil chemotherapy causesrapid bone loss that is reduced by clodronate: a randomized study in premenopuasal breast cancer patients. J Clin Oncol 1997;15:1341-1347
16. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306-3311
17. Vehmanen L, Saarto T, Elomaa I, et al. Long term impact of chemotherapy induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001;37:2373-2378
18. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial and ARNO 95 trial. Lancet 2005;366:455-462
19. Gnant M, Milneritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone mineral density substudy. Lancet Oncol 2008;9:840-849
20. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-629 (Pubitemid 46224240)
21. Osborne C, Tripathy D. Aromatase inhibitors: rationale and use in breast cancer. Ann Rev Med 2005;56:103-116
22. Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002;23:279-302
23. Mincey BA, Duh MS, Thomas SK, et al. Risk of cancer treatment associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 2006;7:127-132
24. Carney JF, Davis J. Emerging bone health issues in women with breast cancer in Hawai'i. Hawaii Med J 2007;66:164-166
25. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007;8:119-127
26. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study of NCIC CTG MA.17. J Clin Oncol 2006;24:3629-3635
27. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829-836
28. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-years results from the Arimidex, Tamoxifen, alone or in combination (ATAC) trial 18233230. J Clin Oncol 2008;26:1051-1057
29. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen Alone or in combination (ATAC) trial. J Bone Miner Res 2006;21:1215-1223
30. Gnant MFX, Milneritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820-828
31. Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23:5126-5137
32. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-661 (Pubitemid 34815869)
33. Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 2002;13:105-112
34. Lindsey R, Christiansen C, Einhorn TA. Consensus development statement: who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 1997;7:1-6
35. Coleman R, Banks LM, Hall E, et al. Intergroup Exemestane study: 1-year results of the bone subprotocol [abstract]. Breast Cancer Res Treat 2005;87:S35
36. Gonnelli S, Cadirni A, Caffarelli C, et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 2007;40:205-220
37. Heshmati HM, Khosla S, Robins SP, et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late menopausal woman. J Bone Miner Res 2002;17:172-177
38. Banerjee S, Smith IE, Folkerd L, et al. Comparative effects of anatsrozole, tamoxifen alone and in combination on plasama lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann Oncol 2005;16:1632-1638
39. Coleman RE, Body JJ, Gralow JR, Lipton A. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev 2008;34:S31-42
40. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092 (Pubitemid 38298988)
41. Kristensen B, Ejlertsen B, Mouridsen HT, et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008;47(4):740-746
42. Howell A, Cuzick J, Baum M, et al. Results of the ATAC trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62
43. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozol and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757
44. Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53
45. Saad F, Adachi JD, Brown JP, et al. Cancer treatment induced bone loss in breast and prostate cancer. J Clin Oncol 2008;26:5465-5476
46. Higano CS. Understanding treatments for bone loss and bone metastasis in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 2004;31:331
47. Morote J, Orsola A, Abascal JM, et al. Bone mineral density changes in patients with prostate cancer durino the first 2 years of androgen suppression. J Urol 2006;175:1679-1683
48. Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005;90:6410-6417
49. Sieber PR, Keiler DL, Kahnoski RJ, et al. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004;171:2272-2276
50. Smith MR, Goode M, Zietman AL, et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004;22:2546-2553
51. Bergstrom I, Gustafsson H, Sjoberg K, et al. Changes in bone mineral density differ between gonadotropin releasing hormone analogue and surgically castrated men with prostate cancer: a prospective controlled, parallel group study. Scand J Urol Nephrol 2004;38:148-152
52. Higano C, Sheilds A, Wood N, et al. Bone mineral density in patients with prostate cancer without bone metastasis treated with intermittent androgen suppression. Urology 2004;64:1182-1186
53. Miyaji Y, Saika T, Yamamoto Y, et al. Effects of gonadotropin releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 2004;64:128-131
54. Prerston DM, Torrens JI, Harding P, et al. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis 2002;5:304-310
55. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat contenta s measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastasis given androgen deptivation therapy. J Urol 2002;167:2361-2367
56. Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002;87:3656-3661
57. Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163:181-186
58. Maillefert JF, Sibilia J, Michel F, et al. Bone mienral density in men treated with synthetic gonadotropin releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219-1222
59. Eriksson S, Eriksson A, Stege R, et al. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1995;57:97-99
60. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology 2005;19:651-658
61. Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin releasing hormone agonists. J Clin Endocrinol Metab 2001;86:2787-2791
62. Kiratli BJ, Srinivas S, Perkash I, et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001;57:127-132
63. Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bnone density. Urology 1999;54:607-611
64. Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005-1007
65. Abrahamsen B, Nielsen MF, Eskildsen P, et al. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int 2007;100:749-754
66. Smith MR, Boyce SP, Moyneur E, et al. Risk of clinical fractures after gonadotropin releasing hormone agonist therapy for prostate cancer. J Urol 2006;175:136-139
67. Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007;177:17-24
68. Smith MR, Lee WC, Brandman J, et al. Gonadotropin releasing hormone agonists and fracture risk: a claims based cohort study of men with non metastatic prostate cancer. J Clin Oncol 2005;23:7897-7903
69. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-1936
70. Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility. N Eng J Med 2006;354:2250-2261
71. Body JJ, Bergmann P, Boonen S, et al. Management of cancer treatment induced bone loss in early breast and prostate cancer- a consensus paper of the Belgian Bone Club. Osteoporos Int 2007;18:1439-1450
72. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of the breast cancer induced bone loss: a consensus position statement from a UK expert group. Cancer Tret Rev 2008;34:S3-18
73. Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008;19:1407-1416
74. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428
75. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057
76. Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892-899
77. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-755
78. Black DM, Delmas PD, Eatsell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822
79. Graham R, Russell G, Espina B, Hulley P. Bone biology and the pathogenesis of osteoporosis. Curr Opin Rheumatol 2006;18(Suppl 1):S3-S10
80. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodelling. J Bone Miner Res 2005;20:177-184
81. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1 - 34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441
82. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in estabilished postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-2066
83. Hamdy NA. Strontium ranelate improves bone microarchitecture in osteoporosis. Rheumatology 2009;48:9-13
84. Schneider A, Kalikin LM, Mattos AC, et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005;146 (4):1727-1736
85. Perez EA, Serene M, Durling FC, Weilbacher K. Aromatase inhibitors and bone loss. Oncology 2006;20(9):1029-1048
86. Saarto T, Blomqvist C, Valimaki M, et al. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 1997;75:602-605
87. Vehmanen L, Saarto T, Risteli J, et al. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat 2004;87:181-188
88. Delmas PD, Balena R, Confraveux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double blind, placebo controlled study. J Clin Oncol 1997;15:955-962
89. Eastell R, Van Poznak CH, Hannon RA, et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12 month analysis. J Bone Miner Res 2007;22(Suppl 1):S113
90. Van Poznak CH, Hannon RA, Clack G, et al. Markers of bone metabolism in postmenopausal women with hormone receptor positive early breast cancer [abstract 156]: SABRE. Presented at 2007 ASCO breast cancer symposium; 7-8 September 2007; San Francisco, CA, USA
91. Greenspan SL, Brufky A, Lembersky BC, et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008;26:2644-2652
92. Hines SL, Mincey BA, Sloan JA, et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopuasal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 2008;27:1047-1053
93. Sawka AM, Ioannidis G, Papaioannou A, et al. Are oral bisphosphonates effective inimproving lumbar bone mineral density in breast cancer survivors with osetopenia or osteoporosis? J Obstet Gynaecol Can 2005;27:759-764
94. Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008;14(19):6336-6342
95. Brufsky A, Bossermann L, Caradonna R, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up. Breast Cancer Res Treat 2007;106:27
96. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008;112:1001-1010
97. De Boer R, Editmann H, Lluch A, et al. The ZO-FAST trial: zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in post-menopausal women with early breast cancer receiving adjuvant letrozole: 24 month BMD results. Breast Cancer Res Treat 2007;(Suppl 1):106:501
98. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007;146(6):416-424
99. Ishizaka K, Machida T, Kobayashi S, et al. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol 2007;14:1071-1075
100. Izumi K, Mizokami A, Sugimoto K, et al. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen deprivation therapy. Urology 2009;73:1342-1346
101. Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade. A double-blind, randomized, placebo-controlled crossover study. Cancer 2001;92(6):1444-1450
102. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-955
103. Israeli RS, Rosenberg SJ, Saltzstein DR, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007;5(4):271-277
104. Bhoopalam N, Campbell SC, Moritz T, et al. Intravenous zolerdronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol 2009;182:2257-2264
105. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin releasing hormone agonist induced bone loss in men with prostate cancer. J Clin Oncol 2007;25:1038-1042
106. Ryan CW, Huo D, Bylow K, et al. Suppression of bone density loss and bone turnover in patients with hormone sensitive prostate cancer and receiving zoledronic acid. BJU Int 2007;100:70-75
107. Ryan CW, Huo D, Demers LM, et al. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006;176:972-978
108. Casey R. Zoledronic acid reduces bone loss in men with prostate cancer receiving goserelin: 12-month results. Presented at the American Society of Clinical Oncology Prostate Cancer Symposium; 22-24, February 2007; Orlando, FL, USA
109. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-2012
110. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPG) directly activates mature osteoclasts. J Cell Biol 1999;145:527-38
111. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176
112. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602
113. Ellis G, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-4882
114. Ellis G, Bone HG, Chlebowski R, et al. Effect of denosumab in bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 2009; doi: 10.1007/s10549-009-0352-y
115. Ettinger B, Black DM, Mitlack BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999;282:637-645
116. Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-1524
117. Lee WL, Chao HT, Cheng MH, Wang PH. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas 2008;60:92-107
118. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: 4-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-3617
119. Barrett-Connor E. raloxifene use for the heart (RUTH) trial investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137
120. Mithal A, Wahl DA, Bonjour JP, et al.; IOF Committee of Scientific Advisors (CSA) Nutrition Working Group. Global vitamin D status and determinants of hypovitaminosis D. Osteoporosis Int 2009;20(11):1807-1820
121. Adami S, Bertoldo F, Braga V, et al. 25-hydroxy vitamin D levels in healthy premenopausal women: association with bone turnover markers and bone mineral density. Bone 2009;45:423-426
122. Glover S, Gall M, Schoenborn-Kellenberger O, et al. Establishing a reference interval for bone turnover markers in 637 healthy young, pre-menopausal women from UK, France, Belgium and the USA. J Bone Miner Res 2009;24:389-397
123. Holick MF. The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanism of action. Mol Aspects Med 2008;19(6):361-368
124. Crew KD, Shane E, Cremers S, et al. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 2009;27:2151-2156
125. Li H, Stampfer MJ, Hollis JB, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms and prostate cancer. PLoS Med 2007;4(3):e103
126. Peterlik M, Grant WB, Cross HS, et al. Calcium, vitamin D and cancer. Anticancer Res 2009;29:3687-3698
127. Chen P, Hu P, Xie D, et al. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat 2009; doi 10.1007/s10549-009-0593-9
128. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281
129. Yin L, Raum E, Haug U, et al. Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol 2009;33:435-445
130. Kawahara M, Iwasaki Y, Sakaguchi K, et al. Predominant role of 25(OH)D in the negative regulation of PTH expression: clinical relevance for hypovitaminosis D. Life Sci 2008;82:677-683
131. Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009;20(2):239-244
132. Berruti A, Tucci M, Generali D, et al. Management of the side-effects of intravenous bisphosphonates: targeting the serum parathyroid hormone elevation. Ann Oncol 2006;17(12):1854-1855
133. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency. A meta analysis of randomized controlled trials. Arch Intern Med 2009;169:551-561
134. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, et al. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int 2009; doi: 10.1007/s00198-009-1119-3
135. Lips P. Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 2004;89-90:611-614
136. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine, National Academy of Sciences. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. National Academy Press. Washington, DC, USA; 2000
137. Amir E, Simmons CE, Freedman OC, et al. A phase 2 trial exploring the effects of high-dose (10000 IU/day) vitamin D3 in breast cancer patients with bone metastases. Cancer 2009; doi: 10.1002/cncr.24749
138. Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles' heel of antifracture efficacy. Osteoporos Int 2007;18:711-719
139. Gallagher A, Rietbrock S, Olson M, et al. Fracture outcomes related to persistence and compliance with oral bisphosphoantes. J Bone Miner Res 2008;23:1569-1575
140. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphopshonates therapy and fracture rates in osteoporotic women: relationship to vertebral and non vertebral fractures from 2 US claims database. Mayo Clin Proc 2006;81:1013-1022
141. Forbes JF, Cizick J, Buzxdar A, et al. Effects of anastrozole and tamoxifene as adjuvant treatment for early-stage breast cancer: 100 month analysis of the ATRAC trial. Lancet Oncol 2008;9:45-53
142. Burkiewicz JS, Scarpace SL, Bruce SP. Denosumab in osteoporosis and oncology. Ann Pharmacother 2009;43:1445-1455
143. Bertoldo F, Tonini G, Vincenzi B. Medical oncology: zoledronic acid prevents bone loss in early stage breat cancer. Nat Rev Clin Oncol 2009;6:192-202
144. Gnant MF, Milneritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid effectively prevents cancer treatment induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820-828
145. Brufsky A, Lund K, Cobb P, et al. Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase innibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (LET) [abstract 5060]. Breast Cancer Res Treat 2006;100(Suppl 1):S233
146. Bertoldo F, Pancheri S, Zenari S, et al. Serum 25(OH)D modulate the acute phase response associated to the first nitrogen containing bisphophonate infusion. J Bone Miner Res 2009, doi: 10.1359/jbmr.090819
147. Khosla S. Bisphosphonates-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. ASBMR Task Force on Bisphosphonate-Associated ONJ. J Bone Miner Res 2007;22(10):1479-1491
148. Grbic JT, Landesberg R, Lin SQ, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008;139(1):32-40
149. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822
150. Mak A, Cheung MWL, Chun-Man Ho R, et al. Bisphosphonates and atrial fibrillation: Bayesan metanalysis of randomized and observational studies. BMC Muscoloskelet Disord 2009;10:113
151. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Maxillofac Surg 2009; doi: 10-1016/j.bjoms.2009. 08.030
152. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture fracture risk in postmenopausal women with osteoporosis: results from a 3 year, randomized, placebo and active controlled clinical trial. J Bone Miner Res 2008;23(12):1923-1934
153. Gallagher JC, Lindsay R, Dietrich J, et al. Smart trials: effects of a tissue selective estrogen complex (TSEC) comprised of bazedoxifene (BZA) and conjugated estrogens (CEs) on bone mineral density (BMD) in postmenopausal women. Fertil Steril 2007;88:S241
154. Lindsay R, Ronkin S, Constantine G, et al. A double-blind, placebo-controlled, phase 3 study of bazedoxifene/conjugated estrogens in postmenopausal women: effects on BMD. Presented at ENDO; June 4 2007; Toronto
155. Cummings SR, Eastell R, Ensrud K, et al. The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial. J Bone Miner Res 2008;23(Suppl 1):S81
156. Bolognese M, Krege JH, Utian WH, et al. Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass. J Clin Endocrinol Metab 2009;94(7):2284-2289
157. Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase III clinical study. J Urol 2008;179:152-155
158. Adami S, Supronik J, Hala T, et al. Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density in postmenopausal women with osteopenia/osteoporosis. J Bone M iner Res 2006;21(Suppl 1):S24
159. Deal C. Future therapeutic targets in osteoporosis. Curr Opin Rheumatol 2009;21:380-385
160. McClung M, Bone H, Cosman F, et al. A randomized, double-blind, placebo-controlled study of odanacatib (MK-822) in the treatment of postmenopausal women with low bone mineral density: 24-month results. J Bone Miner Res 2008;23:S82
161. Padhi D, Stouch B, Fang L, et al. Antisclerostin antibody increases markers of bone formation in healthy postmenopuasal women. J Bone Miner Metab 2007;22(Suppl 1):S37
162. Voorzanger-Rousselot N, Journe F, Doriate V, et al. Assessment of circulating Dikkopf-1with a newtwo-site immunoassay in healthy subjects and women with breast cancer and bonemetastases.CalcifTissue Int 2009;84(5):348-354
163. Agrawal A, Hannon RA, Cheung KL, et al. Bone turnover markers in postmenopausal breast cancer treated with fulvestrant. A pilot study. Breast 2009;18:204-207
164. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106
165. Coleman RE. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer 2009;45(11):1909-1915
166. Monkkonen H, Auriola S, Lehenkari P, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen containing bisphosphonates. Br J Pharmacol 2006;144:437-445
167. Woodward J, Coleman RE, Holen I. Preclinical evidence for the effect of cisphosphonates and cytotoxic drugs on tumor cell invasion. Anticancer Drugs 2005;16:11-19
168. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004;22:233-241
169. Chung U-ki, Schipani E, McMahno AP, Kronanberg HM. Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development. J Clin Invest 2001;107:295-304
170. Long F, Chung U-I, Ohba S, et al. Ihh signalling is directly required for the osteoblast lineage in the endochondral skeleton. Development 2004;131:1309-1318
171. Wan M, Cao X. BMP signaling in skeletal development. Biochem Biophys Res Commun 2005;328:651-657
172. Baron R, Rawadi G. Minireview: targeting the WNT/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007;148(6):2635-2643
173. Faslodex (fulvestrant). AstraZeneca Pharmaceuticals LP; Wilmington, DE, USA; 2004
174. Lea CK, Flanagan AM. Ovarian androgens protect against bone loss in rats made oestrogen deficient by treatment with ICI 182,780. J Endocrinol 1999;160:11-17
175. Mundy GR, Yoneda T, Hiraga T, et al. Preclinical studies with zoledronic acid and other bishosphonates: impact on the bone microenvironment. Semin Oncol 2001;28:35-44
176. Li A, Park J, Melisko M. Zledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Cancer Res 2007:68: abstract 510
177. Rack B, Schindelbeck C, Strobol B, et al. Efficacy of zoledronate in treating persiting isolate tumor cells in bone marrow in patients with breast cancer. A phase II pilot study. Dtsch Med Wochenschr 2008;13(7):285-289
178. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopuasal breast cancer. N Engl J Med 2009;360(7):679-691
179. Freedman OC, Amir E, Clemons MJ. Adjuvant bisphosphonate therapy for breast cancer patients: standard of care or future direction? Crit Rev Oncol Hematol 2009;72(1):56-64
180. Logman F, Heeg B, Botteman M, et al. Cost effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitors: application to the United Kingdom [abstract 1146]. 14th European Cancer Conference (ECCO); September 23-27 2007; Barcellona, Spain